Cardiovascular disease in patients with schizophrenia

  title={Cardiovascular disease in patients with schizophrenia},
  author={Leonard Kritharides and Vincent T. K. Chow and Tim Lambert},
  journal={Medical Journal of Australia},
Patients with schizophrenia die on average 25 years earlier than the general population, and this gap appears to be increasing. Most of the excess mortality is due to premature cardiovascular deaths rather than suicide. Many psychotropic agents are orexigenic and can increase weight and promote dyslipidaemia. Traditional cardiac risk factors are undertreated among patients with schizophrenia, and they are less likely to receive cardiac revascularisation than those without a mental illness… 
Cardiovascular disease in patients with schizophrenia
Coordinated care between tertiary providers, general practitioners and primary health care professionals should monitor the physical health of people with psychosis or schizophrenia at least annually and treatment should be offered accordingly.
Assessment of cardiovascular disease risk factors in patients treated for schizophrenia.
Imposing "healthy" lifestyle as part of clinical management in long-termcare setting in people treated with neuroleptics (atypical or typical) might reduce risk of body mass increase.
Genetic investigations of 100 inherited cardiac disease-related genes in deceased individuals with schizophrenia
It is found that the deceased individuals had a statistically significantly increased polygenic burden caused by variants in the investigated heart genes compared to the general population, which indicates that common variants with smaller effects in heart genes may play a role in schizophrenia.
Cardiometabolic comorbidities and life expectancy in people on medication for schizophrenia in Australia
The results for this study confirm in a large representative Australian sample of people on medication for schizophrenia, an excess risk of components of the metabolic syndrome and early death.
Direct and indirect effects of psychopharmacological treatment on the cardiovascular system
  • K. Kahl
  • Medicine, Psychology
    Hormone molecular biology and clinical investigation
  • 2018
Abstract Background Severe mental disorders, i.e. psychotic disorders, unipolar and bipolar disorders are associated with increased morbidity and mortality from cardiovascular and metabolic
Prevalence of obesity and clinical and metabolic correlates in first-episode schizophrenia relative to healthy controls.
BMI was positively associated with positive symptom severity in FEDN patients and body mass index (BMI) was positively correlated with triglyceride, cholesterol, high-density lipoprotein, low- density lipop protein, triglyceride/high-densitylipoprotein ratio, PANSS positive symptoms, general psychopathology, and total scores.
A sound mind in a sound body- how crucial is a cooperation between medical specialists and patients with coexisting mental and somatic disorders?
Effective management of both mental and somatic disorders is crucial, which requires close multidisciplinary cooperation between a psychiatrist and cardiologist as well as the patient and his family.
Dimensions of improvement: The physical health of people with mental illness
It is clear that the current care system is failing people with a mental illness and new solutions will need to be considered, as much of this new wave of attention is being directed into mental illness as a problem of disability rather than one of improvement.
Living beyond the limitation: Rehabilitation, life and productivity of individuals with schizophrenia in South‐West Nigeria
  • O. OyeladeN. Nkosi-Mafutha
  • Psychology, Medicine
    Health expectations : an international journal of public participation in health care and health policy
  • 2021
The rehabilitation experiences and productivity of individuals with schizophrenia in South‐West Nigeria are described, which decreases the associated stigma.


Life expectancy and cardiovascular mortality in persons with schizophrenia
Schizophrenia is associated with a substantially higher mortality and curtailed life expectancy partly caused by modifiable risk factors, including unhealthy diets, excessive smoking and alcohol use, and lack of exercise.
Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder.
Rosuvastatin proved effective in the management of dyslipidemia in patients with schizophrenia treated with antipsychotics, and more complex treatment may be required for associated metabolic disturbances.
Increased Silent Brain Infarction Accompanied With High Prevalence of Diabetes and Dyslipidemia in Psychiatric Inpatients: A Cross-Sectional Study.
People with schizophrenia have increased risk of atherosclerotic diseases, and participants in this study had an increased ratio of silent brain infarction compared with Japanese healthy controls, accompanied with higher ratios of diabetes and low HDL cholesterol.
Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
To what degree medication‐specific and patient‐specific risk factors interact, and how adverse outcomes can be minimized, allowing patients to derive maximum benefits from these medications, requires adequate clinical attention and further research.
Mental Disorders Across the Adult Life Course and Future Coronary Heart Disease: Evidence for General Susceptibility
Increased risk of incident CHD is present across a range of mental disorders and is observable when disorders are diagnosed at a young age, and rose with exposure to more chronic and perhaps more severe mental disorder.
Twenty-five year mortality of a community cohort with schizophrenia
People with schizophrenia have a mortality risk that is two to three times that of the general population, and most of the extra deaths are from natural causes.